New review charts a roadmap for biologically informed psychiatric diagnosis using biomarkers and AI.
Key Details
- 1Psychiatric diagnosis still relies on symptom checklists, lacking biological grounding.
- 2Emerging frameworks combine molecular/neuroimaging biomarkers, digital phenotyping, and machine learning integration.
- 3Large consortia (e.g., ENIGMA) tie neuroimaging findings to psychiatric conditions like schizophrenia and depression.
- 4Molecular diagnostic tests (e.g., VeriPsych, EDIT-B) have reached limited clinical adoption; most candidate biomarkers lack clinical utility so far.
- 5AI and multimodal models show promise but face challenges with limited psychiatric datasets, lack of explainability, and real-world validation.
- 6Review emphasizes that objective biological measurement should complement—not replace—clinical judgment.
Why It Matters
For radiology and imaging AI professionals, this review highlights the expanding role of neuroimaging, molecular markers, and AI in mental health, a field historically reliant on subjective measures. Robust integration of imaging and digital phenotyping could reshape diagnosis, steering research and technology development towards actionable and explainable clinical tools.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.